Abstract Number: 1443 • 2013 ACR/ARHP Annual Meeting
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Background/Purpose: Albeit lupus occurring on each TNFi have been reported, no epidemiological study has been conducted to assess the link between lupus onset and each…Abstract Number: 1444 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Background/Purpose: Biological therapy has proved efficacious in various chronic inflammatory arthropathies but, in practice, clinical efficacy is reduced in some patients, suggesting drug-induced immunogenicity as…Abstract Number: 1445 • 2013 ACR/ARHP Annual Meeting
GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) forms the backbone of treatment for the majority of patients with rheumatoid arthritis (RA), and is advocated in most guidelines.[i],[ii],[iii] Existing studies imply…Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…Abstract Number: 1447 • 2013 ACR/ARHP Annual Meeting
Success Rate Of 5-Or-More-Week Extended-Interval Therapy With Tocilizumab In Rheumatoid Arthritis Patients In Routine Practice
Background/Purpose: Tocilizumab retreatment is effective and well tolerated in patients with rheumatoid arthritis whose disease activity flared after stopping the therapy. Therefore, reducing tocilizumab dose…Abstract Number: 1448 • 2013 ACR/ARHP Annual Meeting
Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. In Japan, six biological agents have been approved for the treatment…Abstract Number: 1449 • 2013 ACR/ARHP Annual Meeting
Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography
Background/Purpose: The presence of synovitis has been recognized as one of the most important predictive factors of subsequent structural damage in patients with rheumatoid arthritis…Abstract Number: 1450 • 2013 ACR/ARHP Annual Meeting
Safety Of Resuming The Tumor Necrosis Factor Antagonists Therapy In Patients Who Developed Tuberculosis After Use Of Tumor Necrosis Factor Antagonists
Background/Purpose: Tuberculosis is one of the most serious adverse events related to tumor necrosis factor (TNF) antagonists in inflammatory diseases. However, there is no consensus…Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…Abstract Number: 1452 • 2013 ACR/ARHP Annual Meeting
An Early Economic Evaluation Of Personalized Treatment With Rituximab By Prediction Of Effectiveness Using The Interferon Type I Signature In Rheumatoid Arthritis
Background/Purpose: Tailoring therapy to individual patients, for instance by predicting its effectiveness has become increasingly important especially with chronic use of expensive biological DMARDs.To evaluate…Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…Abstract Number: 1454 • 2013 ACR/ARHP Annual Meeting
The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis – Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial
Background/Purpose: Fostamatinib (Fosta) is a spleen tyrosine kinase (SYK) inhibitor in clinical trials in patients (pts) with rheumatoid arthritis (RA). Previous clinical studies showed blood…Abstract Number: 1455 • 2013 ACR/ARHP Annual Meeting
Comparison Of Serum Matrix Metalloproteinase-3 Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 24 Weeks
Background/Purpose : MMP-3 is an enzyme produced by synoviocytes, and is a marker of synovitis that gives a more direct indication of actual joint destruction…Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
ACR Meeting Abstracts